| News
Clinerion launches patient information platform
10.11.2022
Basel-based Clinerion is introducing its machine learning platform. It comprises a global network of hospitals and enables researchers to recognize patterns in large groups of anonymized patient data. It should also make it easier for life science companies to recruit participants for studies.

Clinerion, a global data technology service provider with headquarters in Basel, is bringing its machine learning platform to market. It is linked to a global network of hospitals that provide anonymized electronic patient information, called real-world data, based on their privacy policies. In a press release, Clinerion states that there will be access to 425 million patients in 24 countries. Clinerion has developed its federated machine learning platform together with the Swiss innovation agency Innosuisse, the Bern University of Applied Sciences, and the University of Zurich.
There are two goals for this platform: firstly, it should enable researchers to perform sophisticated analyses and recognize patterns for various illnesses. For example, this would enable high-risk patients to be identified before reaching a critical condition and could be used to find undiagnosed individuals with rare illnesses. Researchers could train models using local data and further optimize them with models from other locations. This would expedite clinical research.
More efficient and efficace
Secondly, the platform aims to “radically” improve the efficiency and efficacy of clinical trial recruitment regarding data-based protocol optimization, location feasibility assessments, and patient screening in real time. Furthermore, it makes it easier for partnering hospitals to participate in these studies.
CEO of Clinerion Barış Erdoğan commented: “Personalized medicine, diversity and inclusion, and rare disease treatment will all benefit from this innovative new technology platform.”
Share this article
Sign up to receive our newsletter in your inbox.
You may also be interested in
VectivBio sold for approximately 1 billion dollars
The takeover of VectivBio is now being finalized: the Boston-based firm Ironwood Pharmaceuticals, which specializes in gastrointestinal medicine, has agreed...
Read MoreUniversity of Basel and RocketVax present new Covid vaccine
Researchers from the University of Basel have developed a new concept for a Covid vaccine in collaboration with the biotech...
Read MoreRami Swiss and Elbit Systems now manufacturing in Jura
The newly established company Rami Swiss has inaugurated a new production facility in Courtételle in the canton of Jura together...
Read MoreBasel to become Europe’s Silicon Valley of biotech
Silicon Valley is synonymous with technology and innovation, and home to dozens of Fortune 1000 companies and thousands of startups....
Read MoreRoche and Novartis among global leaders for research spending
In 2022, Roche invested 16 billion euros in research and development overall. This puts the Basel-based life sciences firm in...
Read MoreRoche to found Institute for Human Biology
Roche has announced that it will be establishing the Institute of Human Biology in Basel. Up to 250 employees will...
Read More